We are live on ! Find out more
EAM

Eventide Asset Management Portfolio holdings

AUM $6.05B
1-Year Est. Return 76.64%
This Fund
S&P 500
This Quarter Est. Return
+5.81%
1 Year Est. Return
+76.64%
3 Year Est. Return
+247.17%
5 Year Est. Return
+285.6%
10 Year Est. Return
+2,546.71%
AUM
$735M
AUM Growth
+$91.2M
Cap. Flow
+$63.4M
Cap. Flow %
8.63%
Top 10 Hldgs %
24.07%
Holding
118
New
17
Increased
44
Reduced
5
Closed
14

Top Buys

Rank Stock Value
1
CELG
Celgene Corp
CELG
+$14.4M
2
SYNA icon
Synaptics
SYNA
+$9.97M
3
DATA
Tableau Software, Inc.
DATA
+$9.41M
4
ACAD icon
Acadia Pharmaceuticals
ACAD
+$4.8M
5
AKBA icon
Akebia Therapeutics
AKBA
+$4M

Top Sells

Rank Stock Value
1
PBYI icon
Puma Biotechnology
PBYI
+$4.68M
2
SJM icon
J.M. Smucker
SJM
+$4.51M
3
NOV icon
NOV
NOV
+$3.7M
4
PCYC
PHARMACYCLICS INC
PCYC
+$2.7M
5
ECYT
Endocyte, Inc. Common Stock
ECYT
+$2.33M

Sector Composition

Rank Sector Weight
1 Healthcare 26.56%
2 Technology 14.37%
3 Consumer Discretionary 13.18%
4 Industrials 9.24%
5 Materials 6.47%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
HPTX
76
DELISTED
HYPERION THERAPEUTICS INC COM STK (DE)
HPTX
$1.99M 0.27%
76,300
+4,600
+6% +$118K
NTUS
77
DELISTED
Natus Medical Inc
NTUS
$1.89M 0.26%
75,000
+3,900
+5% +$96.4K
BMRN icon
78
BioMarin Pharmaceuticals
BMRN
$11.7B
$1.88M 0.26%
30,200
+2,100
+7% +$127K
BRKR icon
79
Bruker
BRKR
$9.79B
$1.79M 0.24%
73,900
– –
SAAS
80
DELISTED
inContact, Inc.
SAAS
$1.78M 0.24%
193,300
– –
INSM icon
81
Insmed
INSM
$22B
$1.77M 0.24%
88,600
+16,600
+23% +$246K
CEMP
82
DELISTED
Cempra, Inc.
CEMP
$1.65M 0.22%
153,800
+10,600
+7% +$102K
CSII
83
DELISTED
Cardiovascular Systems, Inc.
CSII
$1.64M 0.22%
52,700
– –
DRNA
84
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$1.44M 0.2%
+63,700
New +$1.16M
NBIX icon
85
Neurocrine Biosciences
NBIX
$18.7B
$1.43M 0.2%
96,600
+9,300
+11% +$131K
TLPH icon
86
Talphera
TLPH
$70.3M
$1.43M 0.19%
6,970
– –
ARAV
87
DELISTED
Aravive, Inc. Common Stock
ARAV
$1.4M 0.19%
+8,333
New +$1.44M
KPTI icon
88
Karyopharm Therapeutics
KPTI
$159M
$1.4M 0.19%
2,000
-2,520
-56% -$1.17M
ATHN
89
DELISTED
Athenahealth, Inc.
ATHN
$1.39M 0.19%
11,100
+2,200
+25% +$284K
FEIC
90
DELISTED
FEI COMPANY
FEIC
$1.34M 0.18%
14,800
– –
LITS
91
Lite Strategy Inc
LITS
$33.6M
$1.28M 0.17%
10,080
+3,275
+48% +$480K
TGTX icon
92
TG Therapeutics
TGTX
$8.19B
$1.27M 0.17%
+135,000
New +$863K
OMED
93
DELISTED
OncoMed Pharmaceuticals, Inc.
OMED
$1.23M 0.17%
52,800
– –
PCRX icon
94
Pacira BioSciences
PCRX
$1.06B
$1.22M 0.17%
13,300
– –
ARWR icon
95
Arrowhead Research
ARWR
$12.3B
$1.15M 0.16%
+80,000
New +$1.05M
AMBI
96
DELISTED
Ambit Biosciences Corp
AMBI
$1.04M 0.14%
151,100
+20,000
+15% +$140K
XOMA
97
DELISTED
Xoma
XOMA
$813K 0.11%
8,860
-4,000
-31% -$347K
MDSO
98
DELISTED
Medidata Solutions, Inc.
MDSO
$809K 0.11%
18,900
– –
AEGR
99
DELISTED
Aegerion Pharmaceuticals
AEGR
$642K 0.09%
+20,000
New +$745K
TFX icon
100
Teleflex
TFX
$5.86B
$612K 0.08%
5,800
– –
1 2 3
4
5

Similar funds

HPG
Harvest Portfolios Group Oakville, Ontario, Canada $6.06B AUM 16.63% 1-Year Est. Return
EMPI
Elo Mutual Pension Insurance Espoo, Finland $6.06B AUM 24.33% 1-Year Est. Return
RCG
Ruane, Cunniff & Goldfarb New York $6.03B AUM 12.06% 1-Year Est. Return
JWBC
John W. Bristol & Co New York $6.08B AUM 16.51% 1-Year Est. Return
AAM
Advisors Asset Management Monument, Colorado $6.01B AUM 24.74% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return
CM
CastleKnight Management New York $6B AUM 121.87% 1-Year Est. Return
CIS
Capital International Sarl Los Angeles, California $6.11B AUM 32.29% 1-Year Est. Return

Eventide Asset Management's Q2 2014 Portfolio in Review

As of Q2 2014, Eventide Asset Management held 118 positions worth $735M, up 14% from $644M the previous quarter. Its ten largest holdings account for 24% of the portfolio.

Eventide Asset Management deployed $63.4M of net new capital in Q2 2014, opening 17 new positions and adding to 44 existing holdings. Its largest new stake was Celgene Corp: 190,000 shares worth $16.3M.

By sector, the portfolio is most concentrated in Healthcare at 27% of assets, up from 24% a quarter earlier, followed by Technology and Consumer Discretionary.

On the sell side, the largest reduction was PHARMACYCLICS INC, an estimated $2.7M trimmed.

  • Eventide Asset Management's largest Q2 2014 buy was Celgene Corp: 190,000 shares worth $16.3M.
  • Eventide Asset Management added most to Acadia Pharmaceuticals in Q2 2014, an estimated $4.8M increase.
  • Eventide Asset Management's biggest Q2 2014 reduction was PHARMACYCLICS INC, cutting an estimated $2.7M.
  • Eventide Asset Management fully exited Puma Biotechnology in Q2 2014, selling an estimated $4.68M.
  • Eventide Asset Management's ten largest holdings make up 24% of its $735M portfolio in Q2 2014.
  • Eventide Asset Management opened 17 new positions and closed 14 in Q2 2014.
  • Eventide Asset Management's portfolio value rose 14% quarter-over-quarter to $735M.

Based on Eventide Asset Management's 13F filing for Q2 2014, filed 14 Aug 2014.